Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLong-Term Debt IssuancesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsPreferred Shares IssuedProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Bioadaptives (BDPT) EBIAT (2016 - 2025)

Bioadaptives' EBIAT history spans 7 years, with the latest figure at -$823346.0 for Q4 2025.

  • On a quarterly basis, EBIAT fell 121.46% to -$823346.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.6 million, a 73.26% decrease, with the full-year FY2025 number at -$1.6 million, down 73.26% from a year prior.
  • EBIAT hit -$823346.0 in Q4 2025 for Bioadaptives, down from -$379502.0 in the prior quarter.
  • Over the last five years, EBIAT for BDPT hit a ceiling of -$13061.0 in Q3 2023 and a floor of -$823346.0 in Q4 2025.
  • Historically, EBIAT has averaged -$255752.2 across 5 years, with a median of -$246069.0 in 2022.
  • Biggest five-year swings in EBIAT: surged 95.27% in 2023 and later plummeted 908.0% in 2025.
  • Tracing BDPT's EBIAT over 5 years: stood at -$214283.0 in 2021, then soared by 86.8% to -$28277.0 in 2022, then plummeted by 848.83% to -$268301.0 in 2023, then plummeted by 38.57% to -$371788.0 in 2024, then tumbled by 121.46% to -$823346.0 in 2025.
  • Business Quant data shows EBIAT for BDPT at -$823346.0 in Q4 2025, -$379502.0 in Q3 2025, and -$157914.0 in Q2 2025.